Hemab ApS recently presented preclinical data on its human monoclonal antibody against von Willebrand factor (vWF), HMB-002, for the treatment of von Willebrand disease.
CDR-Life Inc. has announced CDR-609 as its next clinical candidate. Built on the company’s proprietary M-gager platform, CDR-609 is a novel T-cell engager targeting LGR5, a surface antigen widely expressed on common solid tumors, including colorectal, gastric, liver and pancreatic cancers.
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of physical exercise by activating skeletal muscle metabolism. Unlike GLP-1-based treatments such as semaglutide and tirzepatide, this new compound, developed by researchers at the Karolinska Institute, Stockholm University, and the biotech company Atrogi AB, does not suppress appetite or cause muscle loss.
In recognition of the fact that diversity, equity and inclusion are necessary prerequisites for precision medicine, the European Academy of Neurology announced the launch of a DEI Hub at its 11th Congress, which is being held in Helsinki through June 24.
Centre Hospitalier Regional Universitaire de Lille, Centre National de la Recherche Scientifique, INSERM, Institut Pasteur de Lille and the University of Lille have prepared and tested new tricyclic spirolactam compounds reported to be useful for the treatment of tuberculosis.
Glucagon-like peptide 1 receptor (GLP-1R) agonists have been detailed in a Fortvita Biologics Inc. patent. They are reported to be useful for the treatment of arthritis, coronary heart diseases, dementia, diabetes, hyperlipidemia, inflammatory bowel diseases, obesity and substance abuse and dependence.
Nanjing Deheng Pharmaceutical Technology Co. Ltd. and Nanjing Delova Biotech Co. Ltd. have discovered new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, cough and pruritus.
Ningbo Newbay Medical Technology Co. Ltd. has identified helicase bicycle amide derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
Healzen Therapeutics Co. Ltd. has patented new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety via a linker. They are reported to be useful for the treatment of cancer, hematological and autoimmune diseases.
Phosphatidylinositol 3-kinases (PI3Ks) are a family of enzymes that catalyze the phosphorylation of phosphatidylinositol at the D-3 position of the inositol ring, serving critical functions in cellular signaling pathways. Among them, the isoform PI3K class II γ (PI3KC2γ), which is predominantly expressed in the liver, regulates hepatic glycogen synthesis and thus plays a critical role in glucose homeostasis.
RSS
